Drug Policy Reform Organizations

The American Academy of Child and Adolescent Psychiatry (AACAP) is a major US professional medical association representing child and adolescent psychiatrists and publisher of the Journal of the American Academy of Child & Adolescent Psychiatry (JAACAP). The organization and its journal have actively engaged with questions around psychedelic-assisted therapy for youth, publishing clinical research and ethical analyses on the potential use of psilocybin and MDMA in adolescent populations.

Longstanding non-profit foundation supporting and convening psychedelic and drug-policy research programs.

US-based nonprofit institute founded by Brazilian anthropologist Dr. Bia Labate that bridges psychedelic plant medicine traditions and emerging clinical science, producing research and accessible cultural commentary on ayahuasca, psilocybin, and other plant medicines while centering Indigenous reciprocity, racial equity, and social justice. Chacruna hosts annual interdisciplinary conferences since 2018, operates a Racial Equity and Access Committee, and amplifies voices of Indigenous peoples, women, queer communities, and the Global South in psychedelic science and policy.

US nonprofit policy advocacy organization working to end the war on drugs through legislation, research translation, and public education, including reforms related to psychedelic policy and decriminalization.

Drug Science is a UK-based independent scientific body that supports evidence-led drug policy and public education, and has played a visible role in psychedelic research translation, communication, and policy discourse.

The European Association for Palliative Care (EAPC) is the leading European professional body for palliative care research, education, and policy, headquartered in Milan. The EAPC is a core consortium partner in PsyPal, the first EU-funded multi-site psilocybin clinical trial (€6.5M), studying psilocybin-assisted therapy for psychological distress in patients with COPD, MS, ALS, and atypical Parkinson's disease across multiple European sites.

Non-profit founded in 2009 and headquartered in Barcelona, dedicated to transforming society's relationship with psychoactive plants including ayahuasca, iboga, and cannabis. ICEERS combines scientific research, legal advocacy, harm reduction services, and ethnobotanical education — including conducting the world's first ibogaine clinical trial for opioid dependency.

The Amsterdam-based European subsidiary of MAPS (Multidisciplinary Association for Psychedelic Studies), MAPS Europe B.V. was established in 2018 to advance MDMA-assisted psychotherapy through EMA-regulated Phase 2 and Phase 3 clinical trials for PTSD across Europe. The organization ran the first multi-site European MDMA/PTSD Phase 2 open-label study with sites in London, Berlin, Lisbon, and others, and trained therapists from 14 countries.

Australian registered charity founded in 2019 that successfully campaigned for the Therapeutic Goods Administration (TGA) to reschedule psilocybin and MDMA in 2023 — making Australia the first country to formally approve these substances for clinical use. MMA trains clinicians through its Certificate in Psychedelic-Assisted Therapies (CPAT) program, funds clinical trials, and has supplied medicines and training to 100+ patients under the TGA Authorised Prescriber scheme.

The National Network of Depression Centers (NNDC) is a US non-profit consortium of academic medical centres united to advance the prevention, diagnosis, and treatment of mood disorders through collaborative research, clinical programmes, and policy advocacy, with member institutions spanning more than 25 major academic health systems. The NNDC supported the BIO-K study, an open-label biomarker development trial investigating intravenous ketamine for non-psychotic unipolar major depression and bipolar I/II depression.

PRISM is an Australian nonprofit organization advancing evidence-based psychedelic science, policy, and public education through research communication, expert engagement, and policy-facing advocacy.

UK drugs policy and legal reform organization advancing rights-based drug policy change, including evidence-led approaches relevant to psychedelic policy and access.

Salt City Psychedelic Therapy and Research (SCPTR) is a Utah-based nonprofit founded by the late Dr. Parth Gandhi to advance psychedelic-assisted therapy through education, research, and advocacy in the Intermountain West. SCPTR organizes the annual Intermountain Psychedelic Symposium and supports practitioners, researchers, and policy reform in the region.

Global youth-led network advocating evidence-based drug policy reform through campus organizing, policy campaigns, and public education that include psychedelic reform issues.

The Swiss Medical Association for Psychedelic Therapy (SÄPT) is a Switzerland-based professional medical association focused on clinical standards, practitioner community building, and responsible development of psychedelic-assisted therapy.

Swiss medical society founded in 1985 whose members received special permission from the Swiss Federal Office of Public Health to conduct psychedelic-assisted therapy with MDMA and LSD in private practices from 1988 to 1993, treating approximately 170 patients. SÄPT continues to advance psycholytic therapy through research, training, and individual treatment licenses, and sponsored the LSD-Assist Study demonstrating persistent anxiety reductions at two-year follow-up.

TheraPsil is a Canadian grassroots nonprofit advancing compassionate, legal access to psilocybin-assisted psychotherapy through clinician training, patient advocacy, and legal reform, having trained over 700 healthcare professionals since 2019. The organization assists Canadians in navigating Health Canada's Special Access Program, supports patient-rights litigation in Federal Court, and operates the PsilWell community-funded clinical trial exploring psilocybin-assisted therapy for general wellbeing.

UK-based policy foundation supporting evidence-driven drug policy reform, including psychedelic policy pathways.